Results 261 to 270 of about 4,210,891 (389)

CBD Hemp Pharming in Illinois: Working to Legitimize an Enduringly Illicit Crop

open access: yesCulture, Agriculture, Food and Environment, EarlyView.
ABSTRACT Based on interviews and participant observation activities conducted in 2024, this article investigates the perspectives and experiences of Illinois farmers cultivating CBD (cannabidiol) hemp. The 2018 U.S. Farm Bill legalized hemp, defined as cannabis containing < 0.3% delta‐9 tetrahydrocannabinol (THC), the intoxicating compound found in ...
Megan A. Styles, Courtney R. Roberts
wiley   +1 more source

Exploratory study of peripheral immune changes associated with diffusion MRI multi‐compartment model in temporal lobe epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective Studies in temporal lobe epilepsy (TLE) have shown that focal inflammation is a key contributor to seizure initiation and maintenance. However, most in vivo studies to date have focused on positron emission tomography (PET) findings. In this exploratory study, we assessed the relationship between multicompartment Neurite Orientation ...
Jerzy P. Szaflarski   +6 more
wiley   +1 more source

Consulting people who use cannabis to plan a regulatory trial on non-medical cannabis sales in pharmacies. [PDF]

open access: yesRes Involv Engagem
Schibli AI   +8 more
europepmc   +1 more source

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

open access: yesEpilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos   +74 more
wiley   +1 more source

Understanding medical cannabis use internationally: Why definitions and context matter. [PDF]

open access: yesAddiction
Graham M   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy